C40

Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Edward Wolin1; Monica Mita1; Tim Meyer2; Johanna Bendell3; Amit Mahipal4; John Nemunaitis5; Pam Munster6; Luis Paz-Ares7; Wayne Hull8; Angela James9; Torsten Trowe10; Mahesh Swaminathan11, Xiaoling Wu11; Hans de Haan10

1Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048
2University College Hospital, London, UK
3SCRI/Tennessee Oncology, PLLC, Nashville, TN 37203
4H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612
5Mary Crowley Cancer Research Center, Dallas, TX 75201
6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
7Hospital Universitario Virgen del Rocío, Seville, Spain
8Celgene Corporation, Basking Ridge, NJ 07920
9Celgene Corporation, Summit, NJ 07901
10Celgene Corporation, San Francisco, CA 94158
11Celgene Corporation, Berkeley Heights, NJ 07922

Background: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223, an ATP-competitive inhibitor of the mTOR kinase, inhibits both TORC1 and TORC2 complexes.

Methods: Subsequent to MTD determination, non-pancreatic NET subjects enrolled in two expansion cohorts using CC-223 starting doses of 45 or 30 mg QD, administered in 28-day cycles until disease progression.

Results: Preliminary results on June 16, 2014 are reported for both dosing cohorts combined. Forty-seven subjects with progression within the prior 12 months while receiving somatostatin analogs (SSA) were treated. The majority of tumors (58%) were midgut with liver metastases; 30/43 (64%) subjects had refractory carcinoid syndrome despite SSA use. The most common (> 20%) related adverse events were diarrhea, stomatitis and fatigue (70% each), rash (65%), nausea (43%), pruritus (39%), hyperglycemia (30%), anorexia (26%), thrombocytopenia and xerostomia (22% each). Dose reduction (30, 20 or 15 mg QD) was required for 74% subjects, usually during cycle 1 or 2; thereafter treatment was well tolerated. Inhibition of TORC1 and TORC2 biomarkers was confirmed in blood cells. Although not prospectively collected, 12/15 (80%) subjects with carcinoid reported marked reduction of flushing and 11/20 (49%) had reduced bowel movements. Symptomatic improvement generally occurred early and persisted despite dose reduction. 9/23 (39%) subjects showed ≥50% reduction in NET-related hormone levels elevated at baseline. Reduction in FDG-PET glucose uptake (≥ 25% SUV) at day 15 was observed in 18/34 (53%) paired scans. Best tumor response (RECIST1.1) in 39 subjects with restaging CTs included stable disease in 35, partial response in 3 and progressive disease in 1. Median treatment duration was 8 cycles (range 1-25 cycles) with a 6-month PFS rate of 85% (68%, 94%).
**Conclusions:** Encouraging signals of biomarker and clinical activity were observed in NET, including prolonged stable disease in the majority of subjects and symptomatic improvement in those with refractory carcinoid syndrome.